Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

61.98USD
27 Mar 2015
Change (% chg)

$-0.44 (-0.70%)
Prev Close
$62.42
Open
$62.25
Day's High
$62.76
Day's Low
$61.80
Volume
1,147,547
Avg. Vol
886,885
52-wk High
$63.05
52-wk Low
$47.37

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $60,145.20
Shares Outstanding(Mil.): 956.55
Dividend: 0.35
Yield (%): 2.19

Financials

  TEVA.N Industry Sector
P/E (TTM): 17.38 40.47 40.89
EPS (TTM): 3.57 -- --
ROI: 8.76 16.76 16.10
ROE: 13.32 17.29 16.95
Search Stocks

Fitch Rates Teva's Euro Bond Offering 'BBB+'

(The following statement was released by the rating agency) CHICAGO, March 24 (Fitch) Fitch Ratings has assigned a 'BBB+' rating to the unsecured Euro bond offering issued by Teva Pharmaceutical Finance Netherlands II, B.V. (Israel) part of Teva Pharmaceuticals Industries Ltd. (Teva). Proceeds are expected to be used for general corporate purposes. Fitch does not expect a material change in total debt balances to result as a net effect of this issuance, the February 2015 tender of USD-denom

24 Mar 2015

BUZZ-India's Natco Pharma jumps; IDFC starts with 'outperformer'

** IDFC initiates coverage of stock with "outperformer" rating and target price of 2,730 rupees

24 Mar 2015

BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia

March 4 - * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and

05 Mar 2015

Teva's internal investigation finds possible corruption

Feb 11 - Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.

12 Feb 2015

UPDATE 1-Israeli drugmaker Teva eyes acquisitions after year of cuts

* Teva seeks growth markets, complex generics, specialty drugs

05 Feb 2015

BRIEF-Teva Pharm CEO on generic Copaxone in 2015

* There might not be any generic Copaxone competition in 2015 but we assume there may be -CEO Further company coverage: (Reporting By Steven Scheer)

05 Feb 2015

BRIEF-Teva Pharm plans 7 drug launches in 2015

* Plans 7 drug launches in 2015 with $400 million of new revenue -CEO Further company coverage: (Reporting By Tova Cohen)

05 Feb 2015

Teva Pharm Q4 profit, revenue meet expectations

TEL AVIV, Feb 5 - Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year.

05 Feb 2015

BUZZ-India's Cipla surges to record high on generic Nexium supply hopes

** India's Cipla rises as much as 4.8 pct to record high of 710 rupees

27 Jan 2015

FDA approves Teva's generic version of AstraZeneca's Nexium

- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

27 Jan 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF96.20 +0.40
Biogen Idec Inc (BIIB.OQ) $429.87 +0.94

Earnings vs. Estimates

Search Stocks